Idelalisib in combination with bendamustine/rituximab improves overall survival in patients with relapsed/refractory CLL: Interim results of a phase 3 randomized double-blind placebo-controlled study Meeting Abstract
| Authors: | Hillmen, P.; Ferra, C.; Garcia-Marco, J.; Jacob, A.; Jurczak, W.; Lamanna, N.; MacDonald, D.; Marlton, P.; Mayer, J.; Morchauser, F.; Nathwani, A.; Schuh, A.; Stilgenbauer, S.; Wierda, W.; Ysebaert, L.; Adewoye, A.; Kim, Y.; Zelenetz, A.; Delgado, J. |
| Abstract Title: | Idelalisib in combination with bendamustine/rituximab improves overall survival in patients with relapsed/refractory CLL: Interim results of a phase 3 randomized double-blind placebo-controlled study |
| Meeting Title: | 21st Congress of the European Hematology Association (EHA) |
| Journal Title: | Haematologica |
| Volume: | 101 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Jun 9-12 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2016-06-01 |
| Start Page: | 433 |
| Language: | English |
| ACCESSION: | WOS:000379484601430 |
| PROVIDER: | wos |
| PMCID: | PMC4894295 |
| Notes: | Meeting Abstract: E1052 -- Source: Wos |
MSK Authors
-
767Zelenetz